Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 3/20 | 0.69 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.69 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.66 |
| ▸ | STS | P08842 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.64 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.62 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5205624 | 0.98 | NPC1 (0.69) | ENPP3ENPP1PTPN1NPC1RAB9A | |
| SCHEMBL8324607 | 0.92 | MTNR1A (0.71) | NPC1RAB9AHTTHPGDMTNR1A | |
| SCHEMBL18877692 | 0.92 | RAB9A (0.64) | ENPP3ENPP1PTPN1NPC1RAB9A | |
| SCHEMBL18877691 | 0.92 | RAB9A (0.64) | ENPP3ENPP1PTPN1NPC1RAB9A | |
| SCHEMBL3995294 | 0.90 | ENPP3 (0.59) | ENPP3ENPP1PTPN1NPC1RAB9A | |
| SCHEMBL125695 | 0.86 | PTPN1 (0.89) | ENPP3ENPP1PTPN1NPC1RAB9A | |
| SCHEMBL28656982 | 0.86 | PTPN1 (0.89) | ENPP3ENPP1PTPN1NPC1RAB9A | |
| SCHEMBL30518933 | 0.86 | MTNR1A (0.64) | NPC1RAB9AHTTMEN1KMT2A | |
| SCHEMBL3197669 | 0.84 | MTNR1A (0.63) | NPC1RAB9AHTTHPGDMTNR1A | |
| SCHEMBL3197659 | 0.84 | MTNR1A (0.63) | NPC1RAB9AHTTHPGDMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114213255-A | Synthetic method of six-membered ring benzylamine compound | 上海泰坦科技股份有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-113226296-A | SSAO inhibitors and uses thereof | 梅塔科林公司 | 2021-08-06 | — | — | CN | disclosed |
| EP-3215142-B1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2021-03-24 | — | — | EP | disclosed |
| CN-102702013-B | Nuclear receptor binding agents | GTX INC. (US) | 2016-02-10 | — | — | CN | disclosed |
| CN-102351732-B | Nuclear receptor binding agents | GTX INC. (US) | 2014-10-29 | — | — | CN | disclosed |
| CN-102702013-A | Nuclear receptor binding agents | GTX INC | 2012-10-03 | — | — | CN | disclosed |
| CN-102351732-A | Nuclear receptor binding agents | GTX INC | 2012-02-15 | — | — | CN | disclosed |
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | UCB PHARMA, S.A. (BE) | 2010-02-11 | — | — | US | disclosed |
| CN-101336227-A | Nuclear receptor binding agents | GTX INC (US) | 2008-12-31 | — | — | CN | disclosed |
| US-7220532-B2 | Chemical amplification type resist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220532-B2 | Chemical amplification type resist composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | HRH4, HRH2, HRH3 | ENPP3 1670/4885ENPP1 1351/4885PTPN1 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.